Menu +

Corcept Therapeutics Announces Poster Presentations on Mifepristone for the Treatment of Patients with Cushing’s Syndrome at the 27th Annual American Association of Clinical Endocrinologists

Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders, today announced that four posters about mifepristone will be presented at the 24th annual American Association of Clinical Endocrinologists (AACE) being held at the Music City Convention Center in Nashville, TN from May 13 – 17, 2015.

“We are pleased that physicians have taken a strong interest in mifepristone and its potential to treat patients with Cushing’s syndrome,” said Joseph K. Belanoff, M.D., Corcept’s Chief Executive Officer.

In addition to presentation of the four abstracts described below, AACE attendees will have the opportunity to attend a “Product Theatre” talk by Ty Carroll, M.D., whose topic will be “Not-So-Subclinical Cushing’s Syndrome.” Corcept is a sponsor of Dr. Carroll’s presentation.

Title  Authors
Friday, May 15, 2015
9:45am – 2:15pm
Poster #131: “Resistant metabolic abnormalities prompting Cushing’s syndrome work-up and treatment with mifepristone” Douglas Beatty, M.D., Rachel Bunta, Dat Nguyen, PharmD
Poster #840: “Mifepristone re-established glycemic control in a Cushing’s syndrome patient that relapsed after a 21 month interruption” Todd Frieze, M.D., James Smith, Ph. D.
Friday, May 15, 2015
10:00am – 10:45am
Product Theater A
Product Theater: “Not-So-Subclinical Cushing’s Syndrome” Ty Carroll, M.D.
Saturday, May 16, 2015
9:45am – 1:00pm
Late-Breaking Poster: “Use of mifepristone in an ectopic Cushing’s syndrome patient pending tumor localization” Adeela Ansari, M.D., Precious Lim, Ph.D., Dat Nguyen, PharmD
Late-Breaking Poster: “Improved response to octreotide LAR for ectopic Cushing’s syndrome during mifepristone therapy: A case study” Andreas Moraitis, M.D., Richard Auchus, M.D.

About Korlym®

Korlym (mifepristone) 300 mg Tablets competitively blocks the glucocorticoid receptor (GR), one of the two receptors to which cortisol normally binds, thereby modulating the effects of excess cortisol in patients with Cushing’s syndrome. Since 2012, Corcept has made Korlym available as a once-daily oral treatment of hyperglycemia secondary to endogenous Cushing’s syndrome in adult patients with glucose intolerance or diabetes mellitus type 2 who have failed surgery or are not candidates for surgery. Korlym was the first FDA-approved treatment for that illness and the FDA has designated it as an Orphan Drug for that indication.

About Cushing’s Syndrome

Endogenous Cushing's syndrome is caused by prolonged exposure of the body's tissues to high levels of the hormone cortisol and is generated by tumors that produce cortisol or ACTH. Cushing’s syndrome is an orphan indication that most commonly affects adults aged 20-50. An estimated 10-15 of every one million people are newly diagnosed with this syndrome each year, resulting in over 3,000 new patients annually in the United States. An estimated 20,000 patients in the United States have Cushing’s syndrome, half of whom are cured by surgery. Symptoms vary, but most people have one or more of the following manifestations: high blood sugar, diabetes, high blood pressure, upper body obesity, rounded face, increased fat around the neck, thinning arms and legs, severe fatigue and weak muscles. Irritability, anxiety, cognitive disturbances and depression are also common. Cushing’s syndrome can affect every organ system in the body and can be lethal if not treated effectively.

About Corcept Therapeutics Incorporated

Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders. Korlym, a first generation competitive GR antagonist, is the company’s first FDA-approved medication. The company is conducting a Phase 1/2 trial of mifepristone for the treatment of triple-negative breast cancer and is planning Phase 2 studies of CORT125134, one of its next-generation selective GR antagonists, for the treatment of Cushing’s syndrome and an oncology indication. The company has developed a proprietary portfolio of other selective GR antagonists that competitively block the effects of cortisol but not progesterone. It owns or has exclusively licensed extensive intellectual property covering the use of GR antagonists, including mifepristone, in the treatment of a wide variety of metabolic, oncologic and psychiatric disorders. It also holds composition of matter patents for its selective GR antagonists.

Investor Contact

Charles Robb, Corcept Therapeutics Incorporated
Chief Financial Officer
crobb@corcept.com
650-688-8783

 

built@zoomedia
You are now leaving this website. If you would like to continue, click Continue.
Cancel Continue